Molecular Medicine

, Volume 23, Issue 1, pp 166–176 | Cite as

An Oligodeoxynucleotide with AAAG Repeats Significantly Attenuates Burn-induced Systemic inflammatory Responses by inhibiting interferon Regulatory Factor 5 Pathway

  • Yue Xiao
  • Wenting Lu
  • Xin Li
  • Peiyan Zhao
  • Yun Yao
  • Xiaohong Wang
  • Ying Wang
  • Zhipeng Lin
  • Yongli Yu
  • Shucheng Hua
  • Liying Wang
Research Article


Previously, we showed that an oligodeoxynucleotide (ODN) with AAAG repeats (AAAG ODN) rescued mice from fatal acute lung injury (ALI) induced by influenza virus and inhibited production of tumor necrosis factor-α (TNF-α) in the injured lungs. However, its underlying mechanisms remain to be elucidated. Upon the bioinformatic analysis revealing that the sequence of AAAG ODN is in consensus with the interferon regulatory factor 5 (IRF5) binding site in the cis-regulatory elements of proinflammatory cytokines, we tried to explore whether AAAG ODN could attenuate burn injury-induced systemic inflammatory responses by inhibiting the IRF5 pathway. Using a mouse model with sterile systemic inflammation induced by burn injury, we found that AAAG ODN prolonged the lifespan of the mice, decreased the expression of IRF5 in the injured skin, reduced the production of TNF-α and IL-6 in the blood and injured skin, and attenuated the ALI. These effects were correlated with AAAG ODN-mediated inhibition of nuclear translocation of IRF5. The data suggest that AAAG ODN could act as a cytoplasmic decoy capable of interfering the function of IRF5 and be developed as a drug candidate for the treatment of inflammatory diseases.



The authors would like to thank Leichao Zhang, Jiwei Liu and Xian Zhang for technical assistance, and acknowledge the contribution of Wei Sun, Xiuping Meng and Shu Nie for analysis strategies. This work was supported by the National Nature Scientific Foundation of China (81471888, 81570002 and 31670937).

Supplementary material

10020_2017_2301166_MOESM1_ESM.pdf (418 kb)
Supplementary material, approximately 418 KB.


  1. 1.
    Zhang Q, et al. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 464:104–7.CrossRefGoogle Scholar
  2. 2.
    Manson J, Thiemermann C, Brohi K. (2012) Trauma alarmins as activators of damage-induced inflammation. Br. J. Surg. 99Suppl 1:12–20.CrossRefGoogle Scholar
  3. 3.
    Kandimalla ER, Zhu FG, Bhagat L, Yu D, Agrawal S. (2003) Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. Biochem. Soc. Trans. 31:654–8.CrossRefGoogle Scholar
  4. 4.
    Takaoka A, et al. (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature. 434:243–9.CrossRefGoogle Scholar
  5. 5.
    Chen W, et al. (2008) Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat. Struc. Mol. Biol. 15:1213–20.CrossRefGoogle Scholar
  6. 6.
    Pelka K, Latz E. (2013) IRF5, IRF8, and IRF7 in human pDCs: the good, the bad, and the insignificant? Eur. J. Immunol. 43:1693–7.CrossRefGoogle Scholar
  7. 7.
    Steinhagen F, et al. (2013) IRF-5 and NF-kappaB p50 co-regulate IFN-beta and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells. Eur. J. Immunol. 43:1896–906.CrossRefGoogle Scholar
  8. 8.
    Sandling JK, et al. (2010) A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur. J. Hum. Genet. 19:479–84.CrossRefGoogle Scholar
  9. 9.
    Allen TC, Kurdowska A. (2014) Interleukin 8 and Acute Lung Injury. Arch. Pathol. Lab. Med. 138:266–9.CrossRefGoogle Scholar
  10. 10.
    Ren JY, Chen X, J.C Zj. (2014) IKKβ is an IRF5 kinase that instigates inflammation. PNAS. 111:17438–43.CrossRefGoogle Scholar
  11. 11.
    Weiss M, et al. (2015) IRF5 controls both acute and chronic inflammation. Proc. Natl. Acad. Sci. USA. 112:11001–6.CrossRefGoogle Scholar
  12. 12.
    Fang M, et al. (2011) An oligodeoxynucleotide capable of lessening acute lung inflammatory injury in mice infected by influenza virus. Biochem. Biophys. Res. Commun. 415:342–7.CrossRefGoogle Scholar
  13. 13.
    Wei Z, et al. (2016) Mangiferin inhibits macrophage classical activation via downregulating interferon regulatory factor 5 expression. Mol. Med. Rep. 14:1091–8.CrossRefGoogle Scholar
  14. 14.
    Zhu W, et al. (2016) Baicalin ameliorates experimental inflammatory bowel disease through polarization of macrophages to an M2 phenotype. Int. Immunopharmacol. 35:119–26.CrossRefGoogle Scholar
  15. 15.
    Li J, Liu Y, Xu H, Fu Q. (2016) Nanoparticle-Delivered IRF5 siRNA Facilitates M1 to M2 Transition, Reduces Demyelination and Neurofilament Loss, and Promotes Functional Recovery After Spinal Cord Injury in Mice. Inflammation. 39:1704–17.CrossRefGoogle Scholar
  16. 16.
    Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies. (2011) Guide for the Care and Use of Laboratory Animals, 8th ed.Google Scholar
  17. 17.
    Zins SR, Amare MF, Anam K, Elster EA, Davis TA. (2010) Wound trauma mediated inflammatory signaling attenuates a tissue regenerative response in MRL/MpJ mice. J. Inflamm. Res. 7:25.CrossRefGoogle Scholar
  18. 18.
    McGill MR, et al. (2014) Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology. 60:1336–45.CrossRefGoogle Scholar
  19. 19.
    Dancey DR, et al. (1999) ARDS in patients with thermal injury. Intensive Care Med. 25:1231–6.CrossRefGoogle Scholar
  20. 20.
    Ipaktchi K, et al. (2006) Attenuating burn wound inflammatory signaling reduces systemic inflammation and acute lung injury. J. Immunol. 177:8065–71.CrossRefGoogle Scholar
  21. 21.
    Schwacha MG, Holland LT, Chaudry IH, Messina JL. (2005) Genetic variability in the immune-inflammatory response after major burn injury. Shock. 23:123–8.CrossRefGoogle Scholar
  22. 22.
    Davis TA, et al. (2009) Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. Int. Wound J. 6:11–21.CrossRefGoogle Scholar
  23. 23.
    Zhang J, Sio SW, Moochhala S, Bhatia M. (2010) Role of hydrogen sulfide in severe burn injury-induced inflammation in mice. Mol. Med. 16:417–24.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Costantini TW, et al. (2009) Burns, inflammation, and intestinal injury: protective effects of an antiinflammatory resuscitation strategy. J. Trauma. 67:1162–8.CrossRefGoogle Scholar
  25. 25.
    Nakazawa H, et al. (2017) iNOS as a Driver of Inflammation and Apoptosis in Mouse Skeletal Muscle after Burn Injury: Possible Involvement of Sirt1 S-Nitrosylation-Mediated Acetylation of p65 NF-kappaB and p53. PloS One. 12:e0170391.CrossRefGoogle Scholar
  26. 26.
    Csontos C, et al. (2010) Time course of pro- and anti-inflammatory cytokine levels in patients with burns: prognostic value of interleukin-10. Burns. 36:483–94.CrossRefGoogle Scholar
  27. 27.
    Jeschke MG, et al. (2011) Insulin protects against hepatic damage postburn. Mol. Med. 17:516–22.CrossRefGoogle Scholar
  28. 28.
    Baird A, et al. (2016) Mice engrafted with human hematopoietic stem cells support a human myeloid cell inflammatory response in vivo. Wound Repair Regen. 24:1004–14.CrossRefGoogle Scholar
  29. 29.
    Takao K, Miyakawa T. (2015) Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA. 112:1167–72.CrossRefGoogle Scholar
  30. 30.
    Chen Z, Zhang Y, Ma L, Ni Y, Zhao H. (2016) Nrf2 plays a pivotal role in protection against burn trauma-induced intestinal injury and death. Oncotarget. 7:19272–83.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Kerby JD, et al. (2006) Sex differences in mortality after burn injury: results of analysis of the National Burn Repository of the American Burn Association. J. Burn Care Res. 27:452–6.CrossRefGoogle Scholar
  32. 32.
    Faggioni R, Moser A, Feingold KR, Grunfeld C. (2000) Reduced leptin levels in starvation increase susceptibility to endotoxic shock. Am. J. Pathol. 156:1781–7.CrossRefGoogle Scholar
  33. 33.
    Okorokov PL, et al. (2012) [Nutritional factors of inflammation induction or lipid mechanism of intestinal endotoxin transport]. Fiziologiia Cheloveka. 38:105–12.PubMedGoogle Scholar
  34. 34.
    Dahiya P. (2009) Burns as a model of SIRS. Front. Biosci. (Landmark Ed.) 14:4962–7.CrossRefGoogle Scholar
  35. 35.
    Nishiura T, et al. (2000) Gene expression and cytokine and enzyme activation in the liver after a burn injury. J. Burn Care Rehabil. 21:135–41.CrossRefGoogle Scholar
  36. 36.
    Yamamoto M, Sato T, Beren J, Verthelyi D, Klinman DM. (2011) The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides. Biomaterials. 32:4238–42.CrossRefGoogle Scholar
  37. 37.
    Farina A, et al. (2014) Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J. Invest. Dermatol. 134:954–64.CrossRefGoogle Scholar
  38. 38.
    Paun A, et al. (2008) Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J. Biol. Chem. 283:14295–308.CrossRefGoogle Scholar
  39. 39.
    Speranskii AI, Kostyuk SV, Kalashnikova EA, Veiko NN. (2016) [Enrichment of extracellular DNA from the cultivation medium of human peripheral blood mononuclears with genomic CpG rich fragments results in increased cell production of IL-6 and TNF-a via activation of the NF-kB signaling pathway]. Biomeditsinskaia Khimiia. 62:331–40.CrossRefGoogle Scholar
  40. 40.
    Barnes BJ, Kellum MJ, Field AE, Pitha PM. (2002) Multiple Regulatory Domains of IRF-5 Control Activation, Cellular Localization, and Induction of Chemokines that Mediate Recruitment of T Lymphocytes. Mol. Cell. Biol. 22:5721–40.CrossRefGoogle Scholar
  41. 41.
    Ikushima H, Negishi H, Taniguchi T. (2013) The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb. Symp. Quant. Biol. 78:105–16.CrossRefGoogle Scholar
  42. 42.
    Xu H, et al. (2012) 4F decreases IRF5 expression and activation in hearts of tight skin mice. PloS One. 7:e52046.CrossRefGoogle Scholar
  43. 43.
    Garg T, Rath G, Goyal AK. (2015) Comprehensive review on additives of topical dosage forms for drug delivery. Drug Delivery. 22:969–87.CrossRefGoogle Scholar
  44. 44.
    Glavas-Dodov M, et al. (2003) 5-fluorouracil in topical liposome gels for anticancer treatment: formulation and evaluation. Acta Pharmaceutica. 53:241–50.PubMedGoogle Scholar
  45. 45.
    Lomas-Neira J, Perl M, Venet F, Chung CS, Ayala A. (2012) The role and source of tumor necrosis factor-alpha in hemorrhage-induced priming for septic lung injury. Shock. 37:611–20.CrossRefGoogle Scholar
  46. 46.
    Zheng H, et al. (2005) Ligustrazine attenuates acute lung injury after burn trauma. Burns. 31:453–8.CrossRefGoogle Scholar
  47. 47.
    Osuchowski MF, Welch K, Siddiqui J, Remick DG. (2006) Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967–74.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Yue Xiao
    • 1
  • Wenting Lu
    • 1
  • Xin Li
    • 1
  • Peiyan Zhao
    • 1
  • Yun Yao
    • 1
  • Xiaohong Wang
    • 2
  • Ying Wang
    • 1
  • Zhipeng Lin
    • 1
  • Yongli Yu
    • 3
  • Shucheng Hua
    • 2
    • 4
  • Liying Wang
    • 1
  1. 1.Department of Molecular Biology, College of Basic Medical Sciences and Institute of Pediatrics, First Hospital, Norman Bethune Health Science CenterJilin UniversityChangchunChina
  2. 2.Department of Respiratory Medicine, The First Hospital of Jilin University, Norman Bethune Health Science CenterJilin UniversityChangchunChina
  3. 3.Department of Immunology, College of Basic Medical Sciences, Norman Bethune Health Science CenterJilin UniversityChangchunChina
  4. 4.Department of Molecular Biology or Department of Respiratory Medicine, College of Basic Medical Sciences and Institute of Pediatrics, First Hospital, or The First Hospital of Jilin University, Norman Bethune Health Science CenterJilin UniversityChangchunChina

Personalised recommendations